Amyloid gains converts in debate over Alzheimer's treatments

Dispute has far-reaching consequences, including whether Medicare will pay for new anti-amyloid drugs.

Full story

#1

Physicians are in short supply. They are costly. Is the APP the answer to the CMO's workforce and budget challenges? ...

Amid the hype and promise, a growing tension is becoming clear: the reality of what AI can deliver versus what it can't. ...